Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leandro Martinez-Pilar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Infection|April 1, 2025
Kerion of the pubisElisabeth Gomez-Moyano, Fatima Moreno-Suarez, Leandro Martinez-Pilar
Pediatric Dermatology|May 1, 2021
Flexural comedones and scar formation caused by inflammatory Tinea corporisJosé Antonio Llamas Carmona, Ángel Vera Casaño, María Trinidad Martin González, et al.
International Journal of Dermatology|March 17, 2020
Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective studyRicardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Manuel Galán-Gutierrez, et al.
Dermatologic Therapy|April 14, 2019
Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric seriesRicardo Ruiz-Villaverde, Javier Dominguez-Cruz, Jose Carlos Armario-Hita, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Infection|April 1, 2025
Kerion of the pubisElisabeth Gomez-Moyano, Fatima Moreno-Suarez, Leandro Martinez-Pilar
Pediatric Dermatology|May 1, 2021
Flexural comedones and scar formation caused by inflammatory Tinea corporisJosé Antonio Llamas Carmona, Ángel Vera Casaño, María Trinidad Martin González, et al.
International Journal of Dermatology|March 17, 2020
Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective studyRicardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Manuel Galán-Gutierrez, et al.
Dermatologic Therapy|April 14, 2019
Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric seriesRicardo Ruiz-Villaverde, Javier Dominguez-Cruz, Jose Carlos Armario-Hita, et al.
Pageof 1